Medical Adjuvants in the Treatment of Surgically Refractory Arteriovenous Malformations of the Head and Face: Case Report and Review of Literature
Open Access
- 1 July 2021
- journal article
- review article
- Published by S. Karger AG in Cerebrovascular Diseases
- Vol. 50 (5) , 493-499
Abstract
Background: Arteriovenous malformations (AVMs) of the brain and face present unique challenges for clinicians. Cerebral AVMs may induce hemorrhage or form aneurysms, while facial AVMs can cause significant disfigurement and pain. Moreover, facial AVMs often draw blood supply from arteries providing critical blood flow to other important structures of the head which may make them impossible to treat curatively. Medical adjuvants may be an important consideration in the management of these patients. Summary: We conducted a systematic review of the literature to identify other instances of molecular target of rapamycin (mTOR) inhibitors used as medical adjuvants for the treatment of cranial and facial AVMs. We also present 2 cases from our own institution where patients were treated with partial embolization, followed by adjuvant therapy with rapamycin. After screening a total of 75 articles, 7 were identified which described use of rapamycin in the treatment of inoperable cranial or facial AVM. In total, 21 cases were reviewed. The median treatment duration was 12 months (3–24.5 months), and the highest recorded dose was 3.5 mg/m2. 76.2% of patients demonstrated at least a partial response to rapamycin therapy. In 2 patients treated at our institution, symptomatic and radiographic improvement were noted 6 months after initiation of therapy. Key Messages: Early results have been encouraging in a small number of patients with inoperable AVM of the head and face treated with mTOR inhibitors. Further study of medical adjuvants such as rapamycin may be worthwhile.Keywords
This publication has 25 references indexed in Scilit:
- Genetic and epigenetic mechanisms in the development of arteriovenous malformations in the brainClinical Epigenetics, 2016
- Treatment of port wine stains using Pulsed Dye Laser, Erbium YAG Laser, and topical rapamycin (sirolimus)—A randomized controlled trialLasers in Surgery and Medicine, 2016
- Topical rapamycin combined with pulsed dye laser in the treatment of capillary vascular malformations in Sturge-Weber syndrome: Phase II, randomized, double-blind, intraindividual placebo-controlled clinical trialJournal of the American Academy of Dermatology, 2015
- Brain AVMs: An Endovascular, Surgical, and Radiosurgical UpdateThe Scientific World Journal, 2014
- Long-Term Outcome of 106 Consecutive Pediatric Ruptured Brain Arteriovenous Malformations After Combined TreatmentStroke, 2014
- Advances and Innovations in Brain Arteriovenous Malformation SurgeryNeurosurgery, 2014
- Variable Somatic TIE2 Mutations in Half of Sporadic Venous MalformationsMolecular Syndromology, 2013
- mTOR and vascular remodeling in lung diseases: current challenges and therapeutic prospectsThe FASEB Journal, 2013
- Measurement of Blood Flow in Arteriovenous Malformations before and after Embolization Using Arterial Spin LabelingInterventional Neuroradiology, 2012
- Sirolimus: its discovery, biological properties, and mechanism of actionTransplantation Proceedings, 2003